Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Revista De La Facultad De Ciencias Medicas (Cordoba, Argentina)
|
January 1, 1995
[Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma]
E Richardet, L Carranza, A Uribe, et al.
JCO Global Oncology
|
March 24, 2022
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study
Ruben D Kowalyszyn, Luis E Fein, Martin E Richardet, et al.
Oncology (Williston Park, N.Y.)
|
August 12, 1999
Uracil/tegafur plus oral calcium folinate in advanced breast cancer
E Richardet, C Pedraza, E Mickiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2001
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients
A Zori Comba, C Blajman, E Richardet, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Revista De La Facultad De Ciencias Medicas (Cordoba, Argentina)
|
January 1, 1995
[Phase II trial with navelbine + cisplatin + etoposide in the treatment of inoperable non-small cell lung carcinoma]
E Richardet, L Carranza, A Uribe, et al.
JCO Global Oncology
|
March 24, 2022
Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study
Ruben D Kowalyszyn, Luis E Fein, Martin E Richardet, et al.
Oncology (Williston Park, N.Y.)
|
August 12, 1999
Uracil/tegafur plus oral calcium folinate in advanced breast cancer
E Richardet, C Pedraza, E Mickiewicz, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 4, 2001
A randomised phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients
A Zori Comba, C Blajman, E Richardet, et al.
ESMO Open
|
May 30, 2025
Nivolumab plus ipilimumab with chemotherapy as first-line treatment of patients with metastatic non-small-cell lung cancer: final, 6-year outcomes from CheckMate 9LA
D P Carbone, T-E Ciuleanu, M Cobo, et al.
ESMO Open
|
October 4, 2021
First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update
M Reck, T-E Ciuleanu, M Cobo, et al.
Page
of 1